Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.

Frontiers in cellular and infection microbiology - 1 Jan 2021

Tang Haijun, Gao Long, Wu Zhao, Meng Fang, Zhao Xin, Shao Yun, Shi Xiaohua, Qiao Shigang, An Jianzhong, Du Xiaohong, Qin F Xiao-Feng

Abstract excerpt

SARS-coronavirus 2 (SARS-CoV-2), pathogen of coronavirus disease 2019 (COVID-19), is constantly evolving to adapt to the host and evade antiviral immunity. The newly emerging variants N501Y.V1 (B.1.1.7) and N501Y.V2 (B.1.351), first reported in the United Kingdom and South Africa respectively, raised concerns due to the unusually rapid global spread. The mutations in spike (S) protein may contribute to the rapid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19
Share to COVID-19 Clinical Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to SARS-CoV-2

Share to SARS-CoV-2 and COVID-19 Research

Share to Spike Glycoprotein, Coronavirus

Share to Viral Infections and Outbreaks Research

Source

Open in PubMed Open full text

Identifiers

PMID: 34722330
DOI: 10.3389/fcimb.2021.720357
PMCID: PMC8549493

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.PMID 34722330Read ↗

Evaluation of Neutralizing Antibodies against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus (Vsv) Pseudovirus-Based AssaySemantic proximity Read ↗

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.Semantic proximity Read ↗

The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape.Semantic proximity Read ↗

Sars-Cov-2 Evolution from the Beginning of Concern to FutureSemantic proximity Read ↗

Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity.Semantic proximity Read ↗

SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike VaccinesSemantic proximity Read ↗

Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assaysSemantic proximity Read ↗

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.Semantic proximity Read ↗

SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 VirusSemantic proximity Read ↗

SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection.Semantic proximity Read ↗

Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity.Semantic proximity Read ↗

Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.